CAR T Cell Persistence via IL-15 Receptor Agonist Combination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR T cell therapies for cancer treatment face challenges such as limited durability of response, high relapse rates, and adverse side effects like cytokine release syndrome and neurotoxicity, necessitating the development of more effective immunotherapeutic strategies that enhance persistence and efficacy of CAR T cells.
Innovation Solution
A combination therapy involving adoptive cell transfer of CAR T cells, specifically CD19-directed CAR T cells, in conjunction with a long-acting IL-15 receptor agonist to stimulate and expand natural killer cells and support CD8+ T cell survival, thereby enhancing anti-tumor immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR T cell therapy is administered to treat cancer, then anti-tumor immune response is activated, but durability of response is limited and relapse rates are high
Solution Approach 1:
The patent modifies the functional state of CAR T cells by blocking inhibitory receptors (PD-1, CTLA-4, TIGIT) and activating co-stimulatory pathways (CD28, 4-1BB, OX40). This parameter change in receptor signaling enables CAR T cells to maintain functional activity and persistence in the tumor microenvironment, directly addressing the durability and relapse issues
Solution Approach 2:
The patent employs a composite immunotherapeutic approach combining CAR T cells with multiple checkpoint modulators and co-stimulatory agents. This composite strategy creates synergistic effects that enhance CAR T cell survival, proliferation, and anti-tumor function, thereby improving response durability and reducing relapse rates
2Quantity of substance
If CAR T cell therapy is administered to treat cancer, then tumor reactive effector T cells are expanded, but poor survival of transferred cells limits long-term efficacy
Solution Approach 1:
The patent applies preliminary conditioning to the tumor microenvironment before CAR T cell infusion, including lymphodepleting chemotherapy and pre-blockade of inhibitory pathways. This preliminary action removes suppressive elements and creates a favorable environment that enhances CAR T cell survival and persistence, directly addressing the poor survival issue
Solution Approach 2:
The patent introduces cytokines (IL-2, IL-7, IL-15, IL-21) and checkpoint modulators as intermediary molecules that mediate between the CAR T cells and the tumor microenvironment. These intermediaries provide survival signals and protective effects, enabling transferred cells to survive longer and maintain functionality
3Reliability
If CAR T cell therapy is administered to treat cancer, then immune system is primed to kill tumor cells, but acute toxicities such as cytokine release syndrome and neurotoxicity occur
Solution Approach 1:
The patent uses controlled dosing strategies and titration of checkpoint modulators to achieve partial activation of immune pathways. This partial action approach stimulates sufficient anti-tumor immunity while avoiding excessive cytokine release and neurotoxicity, directly addressing the toxicity issue
Solution Approach 2:
The patent introduces checkpoint inhibitors and co-stimulatory modulators as intermediary agents that provide controlled, regulated immune activation. These intermediaries act as buffers that prevent runaway immune responses while maintaining effective anti-tumor activity, thereby reducing acute toxicities
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy significantly improves the persistence and efficacy of CAR T cells, leading to enhanced anti-tumor activity, increased CD8+ T cell memory formation, and reduced suppressive regulatory T cells, resulting in improved clinical outcomes with reduced adverse effects.
Implementation Method 1
a long-acting IL-15 receptor agonist to stimulate and expand natural killer cells and support CD8+ T cell survival
Data Source
AI summary
Provided are methods and compositions directed to the treatment of an individual having cancer by (i) administering to the individual an adoptive cellular immunotherapy composition comprising CAR T cells and (ii) administering to the individual an interleukin-15 receptor agonist, such as, for example, a long-acting interleukin-15 receptor agonist.